Abstract Number: 1362 • ACR Convergence 2023
Improving Reproductive Health Counseling for Pediatric Adolescent Females Prescribed Teratogenic DMARDs
Background/Purpose: Several rheumatologic medications routinely prescribed to adolescent females are teratogenic. However, there is no standard method to educate our patients and their families about…Abstract Number: 0194 • ACR Convergence 2023
Reproductive Health Conversations with a Primarily Hispanic Systemic Lupus Erythematosus Population: Influences and Barriers
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease most commonly seen in women of childbearing age, with a greater burden in non-Caucasian populations. The…Abstract Number: 0903 • ACR Convergence 2023
Effects of Hydroxychloroquine on Maternal Outcomes in Pregnant Patients with Systemic Lupus Erythematous
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease, that affects women of childbearing age. SLE is a high-risk condition in pregnant patients due…Abstract Number: 1364 • ACR Convergence 2023
Both Low and High 25(OH)-Vitamin D Levels Increase Adverse Pregnancy Outcomes in Systemic Lupus Erythematosus
Background/Purpose: We evaluated the role of maternal 25(OH)-vitamin D in adverse pregnancy outcomes in systemic lupus erythematosus (SLE). Methods: We used a longitudinal cohort that…Abstract Number: 0463 • ACR Convergence 2023
Appropriate Preconception Care Improves Pregnancy Outcomes in SLE Patients
Background/Purpose: Pregnancies complicated by systemic lupus erythematosus (SLE) are known to be at high risk for adverse pregnancy outcomes (APOs). Previous studies have shown that…Abstract Number: 0979 • ACR Convergence 2023
Use and Discontinuation of Tumour Necrosis Factor Inhibitors Among Pregnant Women with Chronic Inflammatory Diseases
Background/Purpose: Early consensus statements recommended discontinuing tumour necrosis factor inhibitors (TNFi) during pregnancy. Despite new guidelines recommending against this, the choice to stop TNFi pre-conception…Abstract Number: 1571 • ACR Convergence 2023
Tocilizumab in Pregnant Takayasu Arteritis – The Use of Tocilizumab at Conception and Throughout Pregnancy in Those with Takayasu Arteritis
Background/Purpose: Takayasu arteritis (TA) is a large vessel vasculitis predominantly affecting female of reproductive age. Tocilizumab (TCZ) is frequently used in synthetic DMARD refractory cases.…Abstract Number: 0464 • ACR Convergence 2023
Adverse Pregnancy Outcomes in Sjogren’s Disease Compared to Controls: An Interdisciplinary Approach with Maternal Fetal Medicine
Background/Purpose: Outside of the known association of Ro antibody with congenital heart block (CHB), little is known about adverse maternal outcomes, and even less about…Abstract Number: 0986 • ACR Convergence 2023
Medication Use Patterns and Factors Associated with Abnormal Pregnancy Outcomes in Patients with Rheumatoid Arthritis in Korea
Background/Purpose: As female patients constitute a significant proportion of rheumatoid arthritis (RA) cases, pregnancy management is crucial for women with RA. This study aimed to…Abstract Number: 1681 • ACR Convergence 2023
Tacrolimus Use in SLE Pregnancy and Its Effect on Pregnancy Outcomes: Retrospective Study in Two Japanese Tertiary Referral Centers
Background/Purpose: Tacrolimus is one of the major treatment options of systemic lupus erythematosus (SLE) and is thought to be pregnancy compatible medication. Since little is…Abstract Number: 0466 • ACR Convergence 2023
Impact of Postpartum on Patients with Inflammatory Rheumatic Diseases: The P2Rheum Study
Background/Purpose: There are limited data on the impact of the postpartum period (PP) on the activity of inflammatory rheumatic disorders (IRD), and the data available…Abstract Number: 1003 • ACR Convergence 2023
A Multidisciplinary Obstetric-Medicine/Rheumatology Specialty Clinic in the United States: A Five Year Analysis
Background/Purpose: Rheumatic disorders frequently affect women of childbearing age. These diseases and medications used to treat them can have adverse effects on fertility and fetuses.…Abstract Number: 1682 • ACR Convergence 2023
Prospective Evaluation of Anti-SSA/Ro Pregnancies Supports the Utility of High Titer Antibodies and Fetal Home Monitoring for the Detection of Fetal Atrioventricular Block
Background/Purpose: The management of fetuses exposed to maternal anti-SSA/Ro autoantibodies is challenging as the clinician weighs the rarity of fetal atrioventricular block (AVB) against the…Abstract Number: 0467 • ACR Convergence 2023
Cardiovascular Events During Pregnancy: Implications for Adverse Pregnancy Outcomes in Individuals with Autoimmune Rheumatic Diseases and Antiphospholipid Syndrome
Background/Purpose: Autoimmune rheumatic diseases (ARD) and antiphospholipid syndrome (APS) are autoimmune conditions with increased risks of cardiovascular complications as well as negative pregnancy consequences. We…Abstract Number: 1345 • ACR Convergence 2023
Maternal and Infant Outcomes Following Abatacept Exposure During Pregnancy
Background/Purpose: Abatacept is approved for the treatment of moderate to severe rheumatoid arthritis (RA) and psoriatic arthritis. However, there are limited data on the safety…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 15
- Next Page »